| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 273, Issue 4, C1241-C1249, October 1997
Division of Nephrology, 1 Departments of Medicine and 2 Pathology, Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina 29425-2227
After vascular endothelial injury, angiotensin II (ANG II) plays a role in the resulting hypertrophic response, and expression of epidermal growth factor (EGF) is enhanced. Therefore, we tested the possibility that EGF regulates vascular ANG II action and receptor expression. Incubation of cultured aortic vascular smooth muscle cells (VSMC) with EGF (or basic fibroblast growth factor but not platelet-derived growth factor isoforms) resulted in concentration-dependent (1-50 ng/ml EGF), time-dependent (>8 h), and reversible decreases in ANG II surface receptor density. For example, a 50% reduction was observed after exposure to 50 ng/ml EGF for 24 h. Incubation of cultured VSMC with 50 ng/ml EGF for 24 h resulted in a 77% reduction in ANG II-stimulated inositol phosphate formation. EGF not only prevented but also reversed ANG II receptor upregulation by 100 nM corticosterone. The specific tyrosine kinase inhibitor tyrphostin A48 (50 µM) reduced EGF-stimulated thymidine incorporation and EGF-stimulated phosphorylation of mitogen-activated protein kinase but did not prevent EGF from reducing ANG II receptor density. Neither pertussis toxin (100 ng/ml) nor downregulation of protein kinase C by phorbol myristate acetate (100 nM for 24 h) prevented EGF from reducing ANG II receptor density. In summary, EGF is a potent negative regulator of vascular ANG II surface receptor density and ANG II action by mechanisms that do not appear to include tyrosine phorphorylation, pertussis toxin-sensitive G proteins, or phorbol ester-sensitive protein kinase C. The possibility that EGF shifts the cell culture phenotype to one that exhibits reduced surface ANG II density cannot be eliminated by the present studies.
vascular smooth muscle cells; mitogen-activated protein kinase; G proteins
This article has been cited by other articles:
|
|
 |
|
  P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Nickenig and D. G. Harrison The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis: Part II: AT1 Receptor Regulation Circulation, January 29, 2002; 105(4): 530 - 536. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen, Y. V. Mukhin, M. N. Garnovskaya, T. E. Thielen, Y. Iijima, C. Huang, J. R. Raymond, M. E. Ullian, and R. V. Paul A functional angiotensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation Am J Physiol Renal Physiol, September 1, 2000; 279(3): F440 - F448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Xu and T. J. Murphy Reconstitution of Angiotensin Receptor mRNA Down-regulation in Vascular Smooth Muscle. POST-TRANSCRIPTIONAL CONTROL BY PROTEIN KINASE A BUT NOT MITOGENIC SIGNALING DIRECTED BY THE 5'-UNTRANSLATED REGION J. Biol. Chem., March 10, 2000; 275(11): 7604 - 7611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xin, N. Yang, and J. E. Faber Platelet-Derived Growth Factor Inhibits alpha 1D-Adrenergic Receptor Expression in Vascular Smooth Muscle Cells In Vitro and Ex Vivo Mol. Pharmacol., December 1, 1999; 56(6): 1143 - 1151. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Gurantz, R. T. Cowling, F. J. Villarreal, and B. H. Greenberg Tumor Necrosis Factor-{alpha} Upregulates Angiotensin II Type 1 Receptors on Cardiac Fibroblasts Circ. Res., August 6, 1999; 85(3): 272 - 279. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
